"10.1371_journal.pone.0066164","plos one","2013-06-14T00:00:00Z","Daniel Ness; Zhao Ren; Shyra Gardai; Douglas Sharpnack; Victor J Johnson; Richard J Brennan; Elizabeth F Brigham; Andrew J Olaharski","Nonclinical Safety Evaluation, Elan Pharmaceuticals Inc., South San Francisco, California, United States of America; Assay Development, Elan Pharmaceuticals Inc., South San Francisco, California, United States of America; Exploratory Biology, Elan Pharmaceuticals Inc., South San Francisco, California, United States of America; Pharmacology, Elan Pharmaceuticals Inc., South San Francisco, California, United States of America; Thomson Reuters Inc., Carlsbad, California, United States of America; Vet Path Services Inc., Mason, Ohio, United States of America; Burleson Research Technologies Inc. (BRT), Morrisville, North Carolina, United States of America","Conceived and designed the experiments: AJO DN SG DS ZR. Performed the experiments: AJO DS EFB SG. Analyzed the data: SG VJJ AJO RJB. Contributed reagents/materials/analysis tools: SG EFB. Wrote the paper: AJO DN.","Daniel Ness, Zhao Ren, Shyra Gardai, Elizabeth F. Brigham, and Andrew J. Olaharski were employees of Elan Pharmaceutical where the work was conducted. Elan Pharmaceuticals funded this study. Richard J. Brennan is employed by Thomson Reuters Inc., Douglas Sharpnack by Vet Path Services Inc., and Victor J. Johnson by Burleson Research Technologies, Inc. Some work was outsourced to contract research organizations, such as Vet Path Services (Douglas Sharpnack for histopathology), Burleson Research Technologies (Victor J. Johnson for the host resistance study), and Thomson Reuters (Richard J. Brennan for pathway analysis). There are no patents, products in development or marketed products to declare. This does not alter their adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","06","Daniel Ness","DN",8,TRUE,5,4,4,2,TRUE,FALSE,FALSE,0,NA,FALSE
